BIIB Q3 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.4B+11.7% YoY

Gross Profit

$3.0B86.6% margin

Operating Income

$1.7B49.4% margin

Net Income

$1.4B42.0% margin

EPS (Diluted)

$7.15

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

$1.7B

Free Cash Flow

$1.5B

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$25.5B

Total Liabilities

$11.7B

Stockholders' Equity

$13.8B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$3.1B	+11.7%
Gross Profit	$3.0B	$2.7B	+10.0%
Operating Income	$1.7B	$1.7B	+2.6%
Net Income	$1.4B	$1.2B	+17.8%

Revenue Segments

Interferon

$590M39%

TYSABRI product

$470M31%

SPINRAZA

$468M31%

Geographic Segments

UNITED STATES

$1.7B63%

Non-US

$1.0B37%